{
  "ticker": "NYR",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971699",
  "id": "02971699",
  "pages": 5,
  "price_sensitive": true,
  "date": "20250723",
  "time": "0830",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m1lq98lg5d3z.pdf",
  "summary": "### **Material Information Summary**  \n\n- **Phase IIa Trial Announcement** for **Xolatryp\u2122**:  \n  - Target indication: **Acute Myocardial Infarction (AMI)** in **STEMI patients undergoing PCI**.  \n  - **Trial design**: Randomized, double-blind, placebo-controlled, **150 patients**, two doses with **6-hour infusion**.  \n  - **Expected commencement**: **Q1 2026**, pending Phase I completion and HREC approval.  \n  - **Phase I status**: Final cohort dosed with **no safety concerns**; final readouts expected **September 2025**.  \n\n- **Strategic Focus Shift**:  \n  - Priority on **cardioprotection** due to strong preclinical data and limited TBI funding in the US.  \n  - **Stroke & TBI programs** remain active but secondary.  \n\n- **Market Opportunity**: Estimated **950,000 annual PCIs in the US**, with a PCI market size of **US$11.7B (2024)** growing at **10.03% CAGR**.  \n\n- **Preclinical Efficacy**:  \n  - **86% cardioprotective effect** in infarct models (6-hour treatment).  \n  - Significant reduction in arrhythmias (ventricular fibrillation/tachycardia).  \n\n*No capital raising, financials, or trading halt information identified.*",
  "usage": {
    "prompt_tokens": 2730,
    "completion_tokens": 277,
    "total_tokens": 3007,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-22T22:36:20.016473"
}